Hederasaponin B
Based on 1 publication(s) in Google Scholar
Hederasaponin B is an orally active oleanane-type triterpenoid saponin and antiviral agent. Hederasaponin B is isolated from the leaves of Acanthopanax senticosus, Hedera nepalensis var. sinensis, and the rhizomes of Souliea vaginata. Hederasaponin B inhibits the expression of the viral capsid protein VP2 and attenuates virus-induced cytopathic effects. Hederasaponin B exhibits activity against Enterovirus 71 subtypes C3 and C4a. Hederasaponin B shows no hepatoprotective effect against CCl4-induced hepatocyte injury. Hederasaponin B is used in research on hand, foot, and mouth disease.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 99.56%
- No. CAS: 36284-77-2
- Fòrmula: C59H96O25
- Peso molecular:1205.38
-
Almacenamiento:
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Protocolo
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
HY-N0306R
Hederasaponin B (Standard)Enterovirus Inhibitor -
HY-N2584A
IsoxanthohumolFlavonoid compound -
HY-N2562
NorwogoninEnterovirus 71 Inhibitor -
HY-128382
Brilliant Black BNAntiviral Agent -
HY-13784
PirodavirPicornavirus Inhibitor -
HY-16561A
cis-ResveratrolEnteroviruses Inhibitor -
HY-N2036
MosloflavoneEV71 Inhibitor -
HY-104074
PocapavirCapsid Inhibitor -
HY-113204
N-Oleoyl glycineCannabinoid Receptor Activator -
HY-106254
VapendavirEnteroviral Capsid Binder -
HY-145932
DMA-135 hydrochlorideEV71 Inhibitor -
HY-151926
Antiviral agent 24Antiviral Agent
Publications Citing Use of MedChemExpress (MCE) Hederasaponin B
More
Actividad biológica
Descripciòn
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Vero | EC50 |
24.77 μg/mL
|
Inhibition of enterovirus 71 subgenotype C3-induced cytopathic effect in African green monkey kidney Vero cells assessed by sulforhodamine B assay after 48 h incubation.
Inhibition of enterovirus 71 subgenotype C3-induced cytopathic effect in African green monkey kidney Vero cells assessed by sulforhodamine B assay after 48 h incubation.
|
24596620 |
| Vero | EC50 |
41.77 μg/mL
|
Inhibition of enterovirus 71 subgenotype C4a-induced cytopathic effect in African green monkey kidney Vero cells assessed by sulforhodamine B assay after 48 h incubation.
Inhibition of enterovirus 71 subgenotype C4a-induced cytopathic effect in African green monkey kidney Vero cells assessed by sulforhodamine B assay after 48 h incubation.
|
24596620 |
| Vero | CC50 |
>50 μg/mL
|
Cytotoxicity against uninfected African green monkey kidney Vero cells assessed by sulforhodamine B assay after 48 h incubation.
Cytotoxicity against uninfected African green monkey kidney Vero cells assessed by sulforhodamine B assay after 48 h incubation.
|
24596620 |
In Vitro
Hederasaponin B (50 μg/mL; 48 h) strongly inhibits EV71 VP2 capsid protein expression in Vero cells infected with either EV71 C3 or C4a subgenotypes[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:African green monkey kidney (Vero) cells
-
Concentration:50 μg/mL
-
Incubation Time:48 h
-
Result:Dramatically decreased the expression levels of the 34 kDa EV71 VP2 capsid protein in both EV71 C3-infected and EV71 C4a-infected Vero cells.
-
Cell Line:human HepG2 cells
-
Concentration:0.1 μM, 100 μM (tested across the range 0.1-100 μM)
-
Incubation Time:30 min (pre-incubation prior to 0.4% CCl4 exposure for 6 h)
-
Result:Exhibited no hepatoprotective effect against CCl4-induced injury across the entire tested concentration range.
Did not improve cell viability when compared to the CCl4-injured control.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Sprague-Dawley (SD) (male; 200 g)[3]
-
Dosage:150 mg/kg
-
Administration:p.o.; single dose
-
Result:Tentatively identified a total of 47 metabolites in rat biological samples, with 42 detected in feces, 11 in urine, and 9 in plasma.
Observed that deglycosylation was the primary metabolic pathway, accounting for 52.46 % of all metabolites in fecal samples based on semi-quantitative chromatographic peak areas.
Detected four glycosylated metabolites with higher molecular weight than the parent compound, which accounted for 11.55 % of the metabolites in rat feces.
Detected the prototype compound in all three sample matrices (feces, urine, plasma).
Found that the aglycone metabolite oleanolic acid and the deglycosylation metabolite M33 were the most abundant metabolites in feces.
Determined that the fecal route was the main excretion route of hederasaponin B and its metabolites.
Chemical Information
-
No. CAS 36284-77-2
-
Appearance Solid
-
Peso molecular 1205.38
-
Fòrmula C59H96O25
-
Color White to off-white
-
SMILES
O[C@@H]1[C@H](O)[C@@H](O[C@@]2([H])[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@]([H])(O[C@@H]3C(C)(C)[C@@](CC[C@]4(C)[C@@]5(CC=C6[C@]4(CC[C@]7(C(O[C@@H]8O[C@H](CO[C@H]9[C@H](O)[C@@H](O)[C@H](O[C@@]%10([H])[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O%10)[C@@H](CO)O9)[C@@H](O)[C@H](O)[C@H]8O)=O)[C@@]6([H])CC(C)(C)CC7)C)[H])([H])[C@]5(C)CC3)OC1
-
Structure Classification
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Vet Microbiol
The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]2026 May:316:110992. PMID: 41865607
Solvente y solubilidad
In Vitro:
DMSO : 100 mg/mL (82.96 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (2.07 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (2.07 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (300 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Song J, et al. Antiviral Activity of Hederasaponin B from Hedera helix against Enterovirus 71 Subgenotypes C3 and C4a. Biomolecules & therapeutics. 2014 Jan;22(1):41-6. [Content Brief]
[2]. Wua H, et al. A New Cytotoxic Cyclolanostane Triterpenoid Xyloside from Souliea vaginata. Natural product communications. 2017 Feb;12(2):229-232. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 0.8296 mL | 4.1481 mL | 8.2961 mL | 20.7403 mL |
| 5 mM | 0.1659 mL | 0.8296 mL | 1.6592 mL | 4.1481 mL | |
| 10 mM | 0.0830 mL | 0.4148 mL | 0.8296 mL | 2.0740 mL | |
| 15 mM | 0.0553 mL | 0.2765 mL | 0.5531 mL | 1.3827 mL | |
| 20 mM | 0.0415 mL | 0.2074 mL | 0.4148 mL | 1.0370 mL | |
| 25 mM | 0.0332 mL | 0.1659 mL | 0.3318 mL | 0.8296 mL | |
| 30 mM | 0.0277 mL | 0.1383 mL | 0.2765 mL | 0.6913 mL | |
| 40 mM | 0.0207 mL | 0.1037 mL | 0.2074 mL | 0.5185 mL | |
| 50 mM | 0.0166 mL | 0.0830 mL | 0.1659 mL | 0.4148 mL | |
| 60 mM | 0.0138 mL | 0.0691 mL | 0.1383 mL | 0.3457 mL | |
| 80 mM | 0.0104 mL | 0.0519 mL | 0.1037 mL | 0.2593 mL |
Hederasaponin B Related Classifications
HY-N0306 Related Classifications
Powered by Bioz